GRM5 and fragile X syndrome: Recently, there is exciting promise that an mGlu5 inhibitor could target repetitive behaviors generally and self-injury specifically given demonstrable effects on analog behaviors and dendritic architecture in preclinical studies of FXS and autism [48,49].